NCT06018935

Brief Summary

A cohort establishment study of total management of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer).

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2024

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 10, 2023

Completed
21 days until next milestone

First Posted

Study publicly available on registry

August 31, 2023

Completed
10 months until next milestone

Study Start

First participant enrolled

June 17, 2024

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2025

Completed
Last Updated

June 20, 2024

Status Verified

June 1, 2024

Enrollment Period

1.2 years

First QC Date

August 10, 2023

Last Update Submit

June 17, 2024

Conditions

Tumor of Female Reproductive SystemOvarian Cancer

Keywords

Ovarian cancerCohort studyWhole-process management

Outcome Measures

Primary Outcomes (2)

  • Progress Freesurvival (PFS)

    The time from the start of treatment until the patient progresses further or dies.

    Average six months after study completion.

  • Overall Survival (OS)

    Measure the time from the start of treatment to the time of death.

    Average six months after study completion.

Secondary Outcomes (1)

  • Occurrence of adverse reactions

    Average six months after study completion.

Interventions

No interventionOTHER

No intervention

Eligibility Criteria

Sexfemale
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients diagnosed with ovarian cancer (including fallopian tube cancer, primary peritoneal cancer) and intended to be treated in our hospital

You may qualify if:

  • Patients diagnosed with ovarian cancer (including fallopian tube cancer, primary peritoneal cancer) and intended to be treated in our hospital;
  • Can cooperate with later follow-up.

You may not qualify if:

  • Patients with other malignant tumors or previous history of other malignant tumors;
  • Have cognitive impairment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sichuan Cancer Hospital

Chengdu, China

RECRUITING

MeSH Terms

Conditions

Genital Neoplasms, FemaleOvarian Neoplasms

Condition Hierarchy (Ancestors)

Urogenital NeoplasmsNeoplasms by SiteNeoplasmsGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital DiseasesEndocrine Gland NeoplasmsOvarian DiseasesAdnexal DiseasesEndocrine System DiseasesGonadal Disorders

Central Study Contacts

Dengfeng Wang, Learned scholar

CONTACT

15982222707wonderful_96@163.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Deputy chief

Study Record Dates

First Submitted

August 10, 2023

First Posted

August 31, 2023

Study Start

June 17, 2024

Primary Completion

September 1, 2025

Study Completion

September 1, 2025

Last Updated

June 20, 2024

Record last verified: 2024-06

Data Sharing

IPD Sharing
Will not share

Locations

CN(1)